During the corresponding time, Lyell Immunopharma Inc saw a revenue deteriorated by -50 % year on year, sequentially revenue grew by 100 %. While revenue at the Lyell Immunopharma Inc 's corporate clients
Lyell Immunopharma Inc's Comment on Sales, Marketing and Customers
The company is developing ronde-cel to treat patients with aggressive relapsed or refractory large B-cell non-Hodgkin lymphoma (LBCL), targeting subtypes including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (tFL), transformed marginal zone B-cell lymphoma (tMZBCL), transformed mantle cell lymphoma (tMCL), and Grade 3B follicular lymphoma (FL3B). The focus is on patient populations in the United States and worldwide, with an estimated 80,000 NHL diagnoses in the U.S. in 2025 and 545,000 globally. Target patients include those refractory to or relapsing after first-line treatment, progressing to second-line (2L) and third-line or later (3L+) therapies. The market also includes patients treated with CD19 CAR T-cell therapies such as axi-cel and liso-cel, which have limitations in effectiveness and patient eligibility in pivotal trials.
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy Designation for LYL314 in Overcoming Persistent Large B-Cell Lymphoma South San Francisco, California April 15, 2025 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a leader in the clinical development of cutting-edge CAR T cell therapies, has made significant strides in its therapeutic pipeline with the recent designation of LYL314 (formerly known as IMPT314) as a Regenerative Medicine Advanced Therapy (RMAT) by the U.S. Food and Drug Administration (FDA). This coveted designation highlights the promising potential of LYL314 as a treatment for adult patients grappling with relapsed and/or refractory large B-cell lymphoma (LBCL) following two or ...
Lyell Immunopharma Inc’s Comment on Sales, Marketing and Customers
The company is developing ronde-cel to treat patients with aggressive relapsed or refractory large B-cell non-Hodgkin lymphoma (LBCL), targeting subtypes including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (tFL), transformed marginal zone B-cell lymphoma (tMZBCL), transformed mantle cell lymphoma (tMCL), and Grade 3B follicular lymphoma (FL3B). The focus is on patient populations in the United States and worldwide, with an estimated 80,000 NHL diagnoses in the U.S. in 2025 and 545,000 globally. Target patients include those refractory to or relapsing after first-line treatment, progressing to second-line (2L) and third-line or later (3L+) therapies. The market also includes patients treated with CD19 CAR T-cell therapies such as axi-cel and liso-cel, which have limitations in effectiveness and patient eligibility in pivotal trials.
Sources:
Lyell Immunopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Lyell Immunopharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Lyell Immunopharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
150 %